Daiwa Securities Group Inc. Purchases 41 Shares of argenx SE (NASDAQ:ARGX)

Daiwa Securities Group Inc. increased its position in argenx SE (NASDAQ:ARGX) by 2.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,530 shares of the company’s stock after buying an additional 41 shares during the quarter. Daiwa Securities Group Inc.’s holdings in argenx were worth $582,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of ARGX. CWM LLC boosted its stake in shares of argenx by 29.4% in the third quarter. CWM LLC now owns 207 shares of the company’s stock worth $102,000 after acquiring an additional 47 shares during the period. DAVENPORT & Co LLC boosted its stake in argenx by 11.8% in the 3rd quarter. DAVENPORT & Co LLC now owns 1,407 shares of the company’s stock worth $692,000 after purchasing an additional 148 shares during the period. Handelsbanken Fonder AB raised its position in shares of argenx by 5.2% during the third quarter. Handelsbanken Fonder AB now owns 27,466 shares of the company’s stock valued at $13,503,000 after buying an additional 1,364 shares during the last quarter. Raymond James & Associates lifted its holdings in shares of argenx by 132.3% in the third quarter. Raymond James & Associates now owns 33,771 shares of the company’s stock worth $16,603,000 after buying an additional 19,232 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its position in shares of argenx by 15.8% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 11,096 shares of the company’s stock worth $5,455,000 after acquiring an additional 1,518 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Trading Down 1.7 %

Shares of ARGX opened at $368.60 on Friday. The company’s fifty day simple moving average is $386.41 and its 200-day simple moving average is $418.17. The company has a market cap of $21.91 billion, a P/E ratio of -71.71 and a beta of 0.65. argenx SE has a twelve month low of $327.73 and a twelve month high of $550.76.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The firm had revenue of $417.84 million for the quarter, compared to the consensus estimate of $378.60 million. argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. During the same quarter in the previous year, the company posted ($0.70) earnings per share. Analysts predict that argenx SE will post -2.1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ARGX. Truist Financial lifted their price target on shares of argenx from $370.00 to $440.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Wells Fargo & Company lifted their target price on argenx from $472.00 to $478.00 and gave the stock an “overweight” rating in a report on Tuesday, February 20th. HC Wainwright reissued a “buy” rating and set a $451.00 price target on shares of argenx in a research note on Thursday, April 18th. Wedbush reaffirmed an “outperform” rating and issued a $521.00 price objective on shares of argenx in a research note on Thursday, April 18th. Finally, Robert W. Baird decreased their price objective on argenx from $505.00 to $490.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $528.16.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.